Abstract

AbstractThe development of new drugs with activity against breast cancer (MCF‐7) and SARS‐CoV‐2 based on new thiazole derivatives is still of great interest to many scientists. In silico models have been successfully used to orient the design of novel substances, predict IC50 activity, and screen 12 newly designed derivatives of TAZD. The predictive quality of the QSAR models are shown in the statistical values R2train = 0.945, Q2LOO = 0.919, and SE = 8.40 for QSARMLR, and the statistical values R2 = 0.984, Q2test = 0.985, and Q2CV = 0.996 for the QSARANN I(8)‐HL(10)‐O(1) models. The PPI interaction network pharmacological model was used to screen and evaluate the specific effects of TAZDs on target proteins for breast cancer and SARS‐CoV‐2. The obtained TAZD derivatives were consistent in drug‐likeness according to the Lipinski principle. The compound TAZD8 has good inhibitory potential for the 1R42‐PDB protein of breast cancer cells MCF‐7 and the SARS‐CoV‐2 virus. The compound TAZD8 has the ability to strongly bind to the middle region of two proteins, ACE2‐PDB and 6LU7‐PDB. Therefore, thiazole‐based TAZD8 was found to be a derivative with good potential inhibitory activity against Mpro SARS‐CoV‐2 and the 1R42‐PDB protein for breast cancer MCF‐7.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.